The shareholders of the German active pharmaceutical ingredients (API) company PharmaZell have sold 100% of the shares in the company to Ergon Capital Partners II SA. Ergon Capital Partners is a private-equity fund jointly founded by Parcom Capital and GBL Group. The fund is already invested in the API space through its Italian portfolio company Farmabios and intends to fully support PharmaZell's growth plans going forward.

EQT Expansion Capital I has been supporting PharmaZell since 2007 when the Fund provided expansion capital in the form of mezzanine to finance PharmaZell’s growth plans in India and Denmark.